PHASE 3 STUDY OF SAFETY AND IMMUNOGENICITY OF GBP510 VACCINE ADJUVANTED WITH AS03 IN ADULTS

Intro: GBP510 contains the self-assembling recombinant nanoparticle displaying SARS‐CoV-2 Spike protein receptor binding domain and is adjuvanted with AS03. We report interim Phase 3 study (NCT05007951) results up to 4 weeks post-dose 2 (Data-cut: March-18-2022), where immunogenicity to the D614G an...

Full description

Bibliographic Details
Published in:	International Journal of Infectious Diseases
Main Authors:	J.Y. Song, W.S. Choi, H.J. Cheong, H. Kim
Format:	Article
Language:	English
Published:	Elsevier 2023-05-01
Online Access:	http://www.sciencedirect.com/science/article/pii/S1201971223004733

Similar Items

Immunogenicity and protective efficacy of GBP510/AS03 vaccine against SARS-CoV-2 delta challenge in rhesus macaques
by: Catherine Jacob-Dolan, et al.
Published: (2023-02-01)

Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03: interim results of a randomised, active-controlled, observer-blinded, phase 3 trialResearch in context
by: Joon Young Song, et al.
Published: (2023-10-01)

Safety and immunogenicity of an AS03-adjuvanted plant-based SARS-CoV-2 vaccine in Adults with and without Comorbidities
by: Nathalie Charland, et al.
Published: (2022-11-01)

Preparation, characterization and application of MT@SP@GBP and their use for synthesis of novel pyrazolophthalazine-5,10-diones
by: Zahra Alizadeh, et al.
Published: (2025-10-01)

Safety and immunogenicity profiles of an adjuvanted seasonal influenza vaccine in Guatemalan children
by: Adib Rodriguez Solares, et al.
Published: (2014-09-01)

Cytolytic Perforin as an Adjuvant to Enhance the Immunogenicity of DNA Vaccines
by: Ashish C. Shrestha, et al.
Published: (2019-04-01)

A Randomized, Double-Blind, Parallel-Controlled Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of SCT510 to Bevacizumab (Avastin®) in Healthy Chinese Males
by: Jing Wu, et al.
Published: (2023-05-01)

Novel nanoemulsion adjuvant stabilized by TPGS possesses equivalent physicochemical properties, Turbiscan stability, and adjuvanticity to AS03 for eliciting robust immunogenicity of subunit vaccines in mice
by: Quanyi Yin, et al.
Published: (2025-12-01)

Inflammasome-Mediated Immunogenicity of Clinical and Experimental Vaccine Adjuvants
by: Sören Reinke, et al.
Published: (2020-09-01)

The safety and immunogenicity of a cell-derived adjuvanted H5N1 vaccine – A phase I randomized clinical trial
by: Aristine Cheng, et al.
Published: (2019-10-01)

Evervac: phase I/II study of immunogenicity and safety of a new adjuvant-free TBE vaccine cultivated in Vero cell culture
by: Mikhail F. Vorovitch, et al.
Published: (2020-09-01)

Immunogenicity of Different Types of Adjuvants and Nano-Adjuvants in Veterinary Vaccines: A Comprehensive Review
by: Soren Nooraei, et al.
Published: (2023-02-01)

Immunogenicity and Safety of the Recombinant Adjuvanted Herpes Zoster Vaccine in Patients with Chronic Lymphocytic Leukemia and Multiple Myeloma
by: Panagiotis T. Diamantopoulos, et al.
Published: (2024-10-01)

The antibody landscapes following AS03 and MF59 adjuvanted H5N1 vaccination
by: Johannes B. Goll, et al.
Published: (2022-08-01)

Detection of gbpA and gbpB in Streptococcus mutans Isolated from Patients with Oral Potentially Malignant Disorders: A Pilot Study
by: I Shabnam Tamanna, et al.
Published: (2024-07-01)

Immunogenicity and safety of the MF59-adjuvanted seasonal influenza vaccine in non-elderly adults: A systematic review and meta-analysis
by: Alexander Domnich, et al.
Published: (2024-01-01)

Immunogenicity and safety of the MF59-adjuvanted seasonal influenza vaccine in non-elderly adults: A systematic review and meta-analysis.
by: Alexander Domnich, et al.
Published: (2024-01-01)

Next-Generation Influenza HA Immunogens and Adjuvants in Pursuit of a Broadly Protective Vaccine
by: Kaito A. Nagashima, et al.
Published: (2021-03-01)

Immunogenicity of Calvenza-03 EIV/EHV<sup>®</sup> Vaccine in Horses: Comparative In Vivo Study
by: Selvaraj Pavulraj, et al.
Published: (2021-02-01)

Immunogenicity of an adjuvanted broadly active influenza vaccine in immunocompromised and diverse populations
by: Dylan A. Hendy, et al.
Published: (2024-03-01)

Randomized, observer-blind, controlled Phase 1 study of the safety and immunogenicity of the Na-GST-1/Alhydrogel hookworm vaccine with or without a CpG ODN adjuvant in hookworm-naïve adults.
by: David J Diemert, et al.
Published: (2024-12-01)

Immunogenicity of standard, high-dose, MF59-adjuvanted, and recombinant-HA seasonal influenza vaccination in older adults
by: Athena P. Y. Li, et al.
Published: (2021-02-01)

Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 50–64 Years of Age
by: Airi Poder, et al.
Published: (2023-09-01)

Immunogenicity and safety of adjuvant-associated COVID-19 vaccines: A systematic review and meta-analysis of randomized controlled trials
by: Meng-Qun Cheng, et al.
Published: (2023-12-01)

Immunogenicity and Safety of the Quadrivalent Adjuvant Subunit Influenza Vaccine in Seropositive and Seronegative Healthy People and Patients with Common Variable Immunodeficiency
by: Mikhail P. Kostinov, et al.
Published: (2020-11-01)

Safety and immunogenicity of hepatitis B vaccine ButaNG in adults
by: Luzia M. IOSHIMOTO, et al.
Published: (1999-05-01)

Safety and immunogenicity of Clostridium difficile toxoid vaccine in Japanese adults
by: Osamu Matsuoka, et al.
Published: (2018-02-01)

Enhanced Immunogenicity of Adjuvanted Microparticulate HPV16 Vaccines Administered via the Transdermal Route
by: Trinh Phuong Vo, et al.
Published: (2022-09-01)

Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity
by: John J. Suschak, et al.
Published: (2017-12-01)

Do vaccine adjuvant formulations need to be thermodynamically unstable to increase formulation immunogenicity?
by: Shireesh Apte
Published: (2020-03-01)

Enhanced Immunogenicity of Inactivated Dengue Vaccines by Novel Polysaccharide-Based Adjuvants in Mice
by: Shuenn-Jue Wu, et al.
Published: (2022-05-01)

Immunogenicity and Safety Profile of Two Adjuvanted-PD-L1-Based Vaccine Candidates in Mice, Rats, Rabbits, and Cynomolgus Monkeys
by: Camila Canaán-Haden, et al.
Published: (2025-03-01)

Safety and immunogenicity of a SARS-CoV-2 Gamma variant RBD-based protein adjuvanted vaccine used as booster in healthy adults
by: Karina A. Pasquevich, et al.
Published: (2023-07-01)

Immunogenicity and safety of an Entamoeba histolytica adjuvanted protein vaccine candidate (LecA+GLA-3M-052 liposomes) in rhesus macaques
by: Mayuresh M. Abhyankar, et al.
Published: (2024-12-01)

A phase I clinical study to assess safety and immunogenicity of yellow fever vaccine
by: Sajjad Desai, et al.
Published: (2022-12-01)

The Immunogenicity of Capsid-Like Particle Vaccines in Combination with Different Adjuvants Using Different Routes of Administration
by: Christoph M. Janitzek, et al.
Published: (2021-02-01)

Identification of variants in GBP1 and GBP5 Genes associated with susceptibility and resistance to porcine reproductive and respiratory syndrome in Uruguayan Creole pigs
by: María del Carmen Montenegro, et al.
Published: (2024-07-01)

Enhanced immunogenicity of a Clostridioides difficile TcdB vaccine adjuvanted with a synthetic dual-TLR ligand adjuvant
by: Farha Naz, et al.
Published: (2025-02-01)

A phase I, open-label trial on the safety and immunogenicity of the adjuvanted tuberculosis subunit vaccine H1/IC31® in people living in a TB-endemic area
by: Jemal Hussein, et al.
Published: (2018-01-01)

Safety and Immunogenicity of Trivalent Oral Polio Vaccine in Vaccinated Children and Vaccine-Naïve Infants: A Phase 4 Study
by: Luis Rivera Mejía, et al.
Published: (2024-08-01)